mp.weixin.qq.com· 同写意·· 8 hours agoScore34
NorthStar Partners with Quark Pharma to Expand Commercial-Scale Ac-225 Access in China
NorthStar携手夸克医药，拓展商业化规模无载体添加锕-225在中国的可及性 | 会员动态
In brief
NorthStar Medical Technologies and Quark Pharma struck a strategic collaboration on October 14, 2026, covering regulatory filings in China for no-carrier-added actinium-225. Quark Pharma will act as NorthStar's registration agent in China, supporting IND filings for drug developers running clinical studies with NorthStar's n.c.a. Ac-225. NorthStar is the first company to produce n.c.a. Ac-225 at commercial scale using electron accelerator technology.
Source: mp.weixin.qq.com · mp.weixin.qq.com